Search research articles
Contact Us
Filters
Showing results (11-20 of 185) with videos related to
Page
of 19
Sort By:
Journal of Clinical Medicine
|
June 24, 2022
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Roberto Russo, Niccolò Capurro, Emanuele Cozzani, et al.
Frontiers in Medicine
|
November 17, 2022
May bullous pemphigoid be worsened by COVID-19 vaccine?
Emanuele Cozzani, Giulia Gasparini, Roberto Russo, et al.
Dermatologic Therapy
|
December 22, 2019
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Roberto Russo, Emanuele Cozzani, Giulia Gasparini, et al.
BMJ Case Reports
|
December 30, 2025
Subacute cutaneous lupus erythematosus in a patient with Whipple's disease
Gabriele Zanardi, Giulia Merlo, Emanuele Cozzani, et al.
Dermatologic Therapy
|
December 5, 2020
Six months into the pandemic. A review of skin manifestations in SARS-CoV-2 infection
Martina Burlando, Roberto Russo, Emanuele Cozzani, et al.
Mycopathologia
|
December 9, 2022
Generalized Tinea Incognito Developing from "Mask Tinea"
Roberto Russo, Ilaria Trave, Emanuele Cozzani, et al.
Natural Product Research
|
November 29, 2017
The safety assessment of herbals with a new and ethical approach
Eugenio Aiello, Roberto Russo, Claudia Cristiano, et al.
Igiene E Sanita Pubblica
|
January 9, 2007
[Positive predictive value of ICD-9-CM codes in hospital inpatient discharge abstract records, for identifying adverse events]
Maria Michela Gianino, Rosetta Borghese, Roberto Russo, et al.
Pharmacological Research
|
May 22, 2014
Palmitoylethanolamide in CNS health and disease
Giuseppina Mattace Raso, Roberto Russo, Antonio Calignano, et al.
European Journal of Dermatology : EJD
|
June 17, 2020
Acetazolamide: a new trigger for bullous pemphigoid?
Emanuele Cozzani, Andrea Muracchioli, Roberto Russo, et al.
Page
of 19
Search research articles
Search
Showing results (11-20 of 185) with videos related to
Sort By:
Page
of 19
Journal of Clinical Medicine
|
June 24, 2022
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Roberto Russo, Niccolò Capurro, Emanuele Cozzani, et al.
Frontiers in Medicine
|
November 17, 2022
May bullous pemphigoid be worsened by COVID-19 vaccine?
Emanuele Cozzani, Giulia Gasparini, Roberto Russo, et al.
Dermatologic Therapy
|
December 22, 2019
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Roberto Russo, Emanuele Cozzani, Giulia Gasparini, et al.
BMJ Case Reports
|
December 30, 2025
Subacute cutaneous lupus erythematosus in a patient with Whipple's disease
Gabriele Zanardi, Giulia Merlo, Emanuele Cozzani, et al.
Dermatologic Therapy
|
December 5, 2020
Six months into the pandemic. A review of skin manifestations in SARS-CoV-2 infection
Martina Burlando, Roberto Russo, Emanuele Cozzani, et al.
Mycopathologia
|
December 9, 2022
Generalized Tinea Incognito Developing from "Mask Tinea"
Roberto Russo, Ilaria Trave, Emanuele Cozzani, et al.
Natural Product Research
|
November 29, 2017
The safety assessment of herbals with a new and ethical approach
Eugenio Aiello, Roberto Russo, Claudia Cristiano, et al.
Igiene E Sanita Pubblica
|
January 9, 2007
[Positive predictive value of ICD-9-CM codes in hospital inpatient discharge abstract records, for identifying adverse events]
Maria Michela Gianino, Rosetta Borghese, Roberto Russo, et al.
Pharmacological Research
|
May 22, 2014
Palmitoylethanolamide in CNS health and disease
Giuseppina Mattace Raso, Roberto Russo, Antonio Calignano, et al.
European Journal of Dermatology : EJD
|
June 17, 2020
Acetazolamide: a new trigger for bullous pemphigoid?
Emanuele Cozzani, Andrea Muracchioli, Roberto Russo, et al.
Page
of 19